| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 31, 2025 4:01 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $14.00 → $11.00 | Overweight → Equal Weight | Wells Fargo |
| 2/15/2024 | $11.00 | Outperform | Wedbush |
| 1/3/2023 | $18.00 | Equal Weight → Overweight | Wells Fargo |
| 10/13/2022 | $22.00 | Buy | UBS |
| 8/15/2022 | $20.00 | Buy | Jefferies |
| 4/28/2022 | $19.00 | Neutral | Credit Suisse |
| 2/10/2022 | $19.00 | Equal-Weight | Wells Fargo |
| 10/14/2021 | $20.00 | Mkt Perform | SVB Leerink |
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Ros
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase shares of common stock in the proposed offering are to be sold by Monte Rosa. Monte Rosa also intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of share
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg Favorable safety profile observed with mild to moderate adve
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
424B5 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
Wells Fargo downgraded Monte Rosa Therapeutics from Overweight to Equal Weight and set a new price target of $11.00 from $14.00 previously
Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00
Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg Favorable safety profile observed with mild to moderate adve
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.montero
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with stable disease Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant and AR signaling-dependent patients in 2026 Updated MRT-2359 data expected to be presented at ASCO Genitourinary Cancers Symposium in February 2026 Conference call and webcast planned for today at 8 a.m. ET BOSTON, Dec
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)